ClinicalTrials.gg
CompletedNCT00652327Updated Feb 9, 2022Results posted

Comparison of Ezetimibe Added to Ongoing Statin Therapy Versus Doubling the Dose of Statin in the Treatment of Hypercholesterolemia (P04355)

A Phase 4 interventional study of Ezetimibe + Statin (simvastatin, atorvastatin, or pravastatin) and Double Statin (simvastatin, atorvastatin, or pravastatin) in Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-02-09.

Sponsored by Organon and Co · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
83
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.

Enrollment
70th of 97
83 · median 148
Started
2005
with 13 others
Phase 4
31 of 98
1 open now
Registered
33rd of 98
by date
Lead sponsor
55 of 98
Organon and Co

Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 70th largest by enrollment of the 97 interventional ones that give a count, is one of 14 that started in 2005, is one of 31 in phase 4, and was the 33rd registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ezetimibe

Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing ezetimibe in Hypercholesterolemia, or all of them as a file.
02

Study summary

This is a randomized, open label, parallel group comparison study. Following a 1-week screening period, patients will be randomized to 1 of 2 treatment groups: ezetimibe added to ongoing statin treatment (ezetimibe plus simvastatin, atorvastatin or pravastatin at doses of 10/20, 10/10 or 10/20 mg), or doubling the dose of ongoing statin (simvastatin 40 mg, atorvastatin 20 mg, or pravastatin 40 mg). Study drug will be administered once daily in the evening for 8 weeks. Patients will be instructed to follow a National Cholesterol Education Program (NCEP) or similar cholesterol-lowering dietary regimen throughout the study.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

80-120 patients will be recruited in this study. All patients must meet the following criteria and follow an NCEP or similar cholesterol-lowering dietary regimen throughout the study:

  • Men or women ≧18 and ≦80 years of age (Female patients receiving hormone therapy [including hormone replacement therapy, and estrogen antagonist/agonist, or oral ] and maintained on a stable dose and regimen for at least 8 weeks prior to visit 1 must be willing to continue the same regimen throughout the study. Females of must be using a medically acceptable method of birth control).
  • Willing to follow an NCEP Therapeutic Lifestyle Changes (TLC) or similar cholesterol-lowering diet for the duration of the study.
  • Patients with hypercholesterolemia who cannot achieve the optimal therapeutic goal with previous statin treatment (simvastatin 20 mg, atorvastatin 10 mg or pravastatin 20 mg alone for at least 12 weeks) will be enrolled into study. The treatment goal in primary prevention is LDL-C \<160 mg/dL or LDL-C \<130 mg/dL patient with ≧ 2 risk factors (risk factors: hypertension, male ≧ 45 years old, family of premature coronary artery disease [CAD], female ≧ 55 years old or menopause without hormone replace therapy, smoking); LDL-C ≤ 100 mg/dL in CAD patients (documented by coronary angiogram, positive treadmill test or thallium scan), or diabetes mellitus (DM) patients (Ante Cibum [AC][fasting plasma glucose] >126 mg/dL, Post Cibum [PC] [oral glucose tolerance test] > 200 mg/dL, World Health Organization criteria), ischemic stroke (neurological dysfunction with documented diagnosis with computed tomography [CT] or magnetic resonance imaging [MRI]), peripheral artery disease.
  • Triglyceride (TG) concentrations ≦ 400 mg/dL.
  • Liver transaminases ( [ALT] and aspartate aminotransferase [AST]) ≦ 2 x (ULN) with no active liver disease and creatine kinase (CK) ≦ 2 x ULN at screen visit.

Exclusion criteria

Exclusion Criteria:

The following conditions preclude patients from entry into this study:

  • Women who are pregnant or lactating.
  • History of mental instability, drug/alcohol abuse within the past 5 years, or major psychiatric illness not adequately controlled and stable on pharmacotherapy
  • Patients who have been treated with any other drug within 3 months of visit 1.
  • Patients previously randomized to a study with ezetimibe.
  • Active liver disease or Impaired liver function tests (, AST > 2xULN).
  • Impaired renal function ( serum creatinine ≧1.5 mg/dL) or nephrotic syndrome at visit 1
  • Unstable angina
  • Acute myocardial infarction, coronary bypass surgery within the previous six months of visit 1.
  • Uncontrolled cardiac arrhythmias
  • Uncontrolled hypertension (treated or untreated) with systolic blood pressure > 160 mmHg or diastolic > 100 mmHg at visit 1.
  • Poorly controlled diabetes mellitus patient (Patients who are under insulin injection and >10.0%). If the patient is treated with medication for diabetes, the medication will be unchanged during the study period.
  • Uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoprotein, e.g. hypothyroidism (thyroid-stimulating hormone [TSH] > 5.5 uIU/mL). However, patients who are on a stable therapy of thyroid replacement therapy for at least 6 weeks are eligible for enrollment.
  • Patients hypersensitive to HMG-CoA reductase inhibitors or ezetimibe.
  • Patient who is unable to give (the patient with a legal representative to sign the informed consent is eligible to participate the study).
  • Any condition or situation which, in the opinion of the investigator, might pose a risk to the patient or confound the results of the study.
  • Prohibited concomitant therapies.

    • Medications that are potent inhibitors of , including cyclosporine, systemic itraconazole or ketoconazole, erythromycin or clarithromycin, nefazodone, verapamil and (HIV) protease inhibitors.
    • Lipid-lowering agents including fish oils, Cholestin, bile-acid sequestrants, and niacin (\<200 mg/day) taken within 6 weeks and fibrates taken within 8 weeks prior to enrollment.
    • Oral unless used as replacement therapy for pituitary/adrenal disease and treated with a stable regimen for at least 6 weeks prior to enrollment.
    • Treatment with psylium, other fiber-based laxatives, and/or over-the-counter (OTC) therapies known to affect serum lipid levels, phytosterol margarines, unless treated with a stable regimen for at least 6 weeks prior to enrollment, and patient agrees to remain on constant regimen for the duration of the study.
  • Patient is consuming > 250 ml of grapefruit juice per day.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
83 participants (actual)

Study arms

  • Experimental
    Ezetimibe + Statin

    Drug: Ezetimibe + Statin (simvastatin, atorvastatin, or pravastatin)

  • Active comparator
    Double Statin

    Drug: Double Statin (simvastatin, atorvastatin, or pravastatin)

Interventions

  • DrugEzetimibe + Statin (simvastatin, atorvastatin, or pravastatin)

    Drug pages: Ezetimibe · Statins

    ezetimibe 10 mg plus ongoing statin (simvastatin 20 mg or atorvastatin 10 mg or pravastatin 20 mg) once daily for 8 weeks

  • DrugDouble Statin (simvastatin, atorvastatin, or pravastatin)

    simvastatin 40 mg or atorvastatin 20 mg or pravastatin 40 mg once daily for 8 weeks

06

What researchers measure

Primary outcomes

  1. Percentage Change in Low Density Lipoprotein-Cholesterol (LDL-C) From Baseline at Study Endpoint, After 8 Weeks of Treatment

    Time frame: Assessed at the end of 8 weeks of treatment (from baseline to endpoint)

07

Results

Posted Jun 10, 2010

Participant flow

Participant flow — Overall Study
MilestoneEzetimibe + StatinDouble Statin
Started4241
Completed4236
Not completed05
Withdrew: Adverse event02
Withdrew: Lost to follow-up03

Outcome measures

PrimaryPercentage Change in Low Density Lipoprotein-Cholesterol (LDL-C) From Baseline at Study Endpoint, After 8 Weeks of Treatment
Time frame:
Assessed at the end of 8 weeks of treatment (from baseline to endpoint)
Reported as:
Mean · Percentage change
Percentage Change in Low Density Lipoprotein-Cholesterol (LDL-C) From Baseline at Study Endpoint, After 8 Weeks of Treatment
Percentage changeEzetimibe + StatinDouble Statin
Percentage Change in Low Density Lipoprotein-Cholesterol (LDL-C) From Baseline at Study Endpoint, After 8 Weeks of Treatment-26.56 ± 19.78-9.7 ± 21.07
Statistical analysis
  • Ezetimibe + Statin vs Double Statin · Wilcoxon rank sum test · p = .0026

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ezetimibe + Statin—1/42 (2.4%)0/42 (0%)
Double Statin—0/41 (0%)3/41 (7.3%)
Most frequent serious events
Most frequent serious events
EventEzetimibe + StatinDouble Statin
upper respiratory tract infectionInfections and infestations1/420/41
Most frequent other events
Most frequent other events
EventEzetimibe + StatinDouble Statin
vertigoEar and labyrinth disorders0/423/41

Baseline characteristics

Age, Customized
Age, Customized(Participants)Ezetimibe + StatinDouble StatinTotal
<=18 years000
Between 18 and 83 years424183
>=83 years000
Sex: Female, Male
Sex: Female, Male(Participants)Ezetimibe + StatinDouble StatinTotal
Female191837
Male232346
Region of Enrollment
Region of Enrollment(Participants)Ezetimibe + StatinDouble StatinTotal
Taiwan, Province Of China424183
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Yu CC, Lai WT, Shih KC, Lin TH, Lu CH, Lai HJ, Hanson ME, Hwang JJ. Efficacy, safety and tolerability of ongoing statin plus ezetimibe versus doubling the ongoing statin dose in hypercholesterolemic Taiwanese patients: an open-label, randomized clinical trial. BMC Res Notes. 2012 May 23;5:251. doi: 10.1186/1756-0500-5-251. PubMed 22621316 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2005, a primary completion of Jul 2007 and a completion of Jul 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2010, 2 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2008
First posted
Apr 3, 2008
Start
Dec 2005
Primary completionActual
Jul 2007
CompletionActual
Jul 2007
Results first posted
Jun 10, 2010
Last update
Feb 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00652327
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Apr 3, 2008
Start date
Dec 2005
Primary completion
Jul 2007
Completion
Jul 2007
Results posted
Jun 10, 2010
Last update
Feb 9, 2022

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ezetimibe · Statins

Start the discussion